Publications by authors named "S H Astrow"
Article Synopsis
- MAGE-A is a cancer-associated antigen expressed in various tumors but has limited presence in normal tissues; this study focused on its expression in urinary bladder and lung cancers while evaluating the immune environment.
- The researchers analyzed MAGE-A and PD-L1 levels in tumor samples using immunohistochemistry and RNA sequencing, finding that 57% of samples showed detectable MAGE-A expression, with no significant difference between the two cancer types.
- Treatment with checkpoint inhibitors did not alter MAGE-A expression or other immune markers in urothelial carcinoma, suggesting that previous tumor samples can still be useful for evaluating MAGE-targeted treatments.
Genetically engineered T cell therapy can induce remarkable tumor responses in hematologic malignancies. However, it is not known if this type of therapy can be applied effectively to epithelial cancers, which account for 80-90% of human malignancies. We have conducted a first-in-human, phase 1 clinical trial of T cells engineered with a T cell receptor targeting HPV-16 E7 for the treatment of metastatic human papilloma virus-associated epithelial cancers (NCT02858310).
View Article and Find Full Text PDFBackground: Melanoma-associated antigen-A (MAGE-A) and programmed-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We assessed survival outcomes in patients with MAGE-A and PD-L1 expression.
Methods: MAGE-A and PD-L1 expression on neoplastic cells was analyzed using tissue microarrays from patients with UC.
Molecular differences in tumor locations may contribute to the sidedness-specific response to cetuximab in metastatic colorectal cancer (mCRC). We investigated genes associated with the response to cetuximab treatment depending on tumor sidedness. Our study included 77 patients with mCRC (13/63, right/left) with exon 2 wild-type tumors from phase II trials of first-line therapy with cetuximab.
View Article and Find Full Text PDFBackground: Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear.
Patients And Methods: In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel.